Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval.

MLA

Cortes-Blanco, Anabel, et al. “Florbetapir (18F) for Brain Amyloid Positron Emission Tomography: Highlights on the European Marketing Approval.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, vol. 10, no. 5, Oct. 2014, pp. S395–99. EBSCOhost, https://doi.org/10.1016/j.jalz.2013.09.007.

APA

Cortes-Blanco, A., Prieto-Yerro, C., Martinez-Lazaro, R., Zamora, J., Jiménez-Huete, A., Haberkamp, M., Pohly, J., Enzmann, H., Zinserling, J., Strassmann, V., & Broich, K. (2014). Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 10(5), S395–S399. https://doi.org/10.1016/j.jalz.2013.09.007

Chicago

Cortes-Blanco, Anabel, Concha Prieto-Yerro, Raul Martinez-Lazaro, Javier Zamora, Adolfo Jiménez-Huete, Marion Haberkamp, Johannes Pohly, et al. 2014. “Florbetapir (18F) for Brain Amyloid Positron Emission Tomography: Highlights on the European Marketing Approval.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 10 (5): S395–99. doi:10.1016/j.jalz.2013.09.007.